External and implanted pumps for apomorphine infusion in parkinsonism.
Identifieur interne : 001687 ( PubMed/Curation ); précédent : 001686; suivant : 001688External and implanted pumps for apomorphine infusion in parkinsonism.
Auteurs : P. Pollak [France] ; A L Benabid ; P. Limousin ; C L Gervason ; E. Jeanneau-NicolleSource :
- Acta neurochirurgica. Supplementum ; 1993.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (therapeutic use), Adult, Aged, Animals, Apomorphine (administration & dosage), Apomorphine (pharmacology), Apomorphine (therapeutic use), Female, Humans, Infusion Pumps, Implantable, Macaca fascicularis, Male, Middle Aged, Motor Activity (drug effects), Parkinson Disease (drug therapy), Receptors, Dopamine (drug effects).
- MESH :
- chemical , administration & dosage : Apomorphine.
- chemical , drug effects : Receptors, Dopamine.
- chemical , pharmacology : Apomorphine.
- chemical , therapeutic use : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Apomorphine.
- drug effects : Motor Activity.
- drug therapy : Parkinson Disease.
- Adult, Aged, Animals, Female, Humans, Infusion Pumps, Implantable, Macaca fascicularis, Male, Middle Aged.
Abstract
Continuous delivery of dopaminergic agents to the striatum is a major challenge to improve the treatment of Parkinson's disease. Apomorphine is one of the best candidates because of its solubility and its D1 and D2 receptor agonist properties. Seventeen Parkinsonian patients suffering from severe L-dopa-induced on-off effects were treated by continuous subcutaneous (SC) infusion with a portable minipump. Administration of intracerebroventricular (ICV) apomorphine was carried out in 7 macaca fascicularis monkeys using implanted programmable pumps. Four of the monkeys were made Parkinsonian by MPTP injections. In patients receiving apomorphine, the mean duration of daily off periods was reduced by 61%. Psychiatric side effects were rare but SC nodules occurred in all patients and the external infusion method was therefore difficult to implement. In monkeys, the implanted system was well tolerated. ICV apomorphine infusion led to CSF apomorphine concentrations higher than the same apomorphine dose infused i.m. Motor function was considerably improved in two MPTP monkeys during the time of ICV infusion and 30 min after its arrest. Long-term ICV administration could not be carried out because of catheter blockage and/or apomorphine toxicity. SC and ICV apomorphine infusions are efficient for controlling motor activity in Parkinsonism but long-term toxicity remains to be studied further.
PubMed: 8109301
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001728
Links to Exploration step
pubmed:8109301Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">External and implanted pumps for apomorphine infusion in parkinsonism.</title>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical and Biological Neurosciences, INSERM U-318, Joseph Fourier University of Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM U-318, Joseph Fourier University of Grenoble</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A L" last="Benabid">A L Benabid</name>
</author>
<author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P" last="Limousin">P. Limousin</name>
</author>
<author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C L" last="Gervason">C L Gervason</name>
</author>
<author><name sortKey="Jeanneau Nicolle, E" sort="Jeanneau Nicolle, E" uniqKey="Jeanneau Nicolle E" first="E" last="Jeanneau-Nicolle">E. Jeanneau-Nicolle</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1993">1993</date>
<idno type="RBID">pubmed:8109301</idno>
<idno type="pmid">8109301</idno>
<idno type="wicri:Area/PubMed/Corpus">001728</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001728</idno>
<idno type="wicri:Area/PubMed/Curation">001687</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001687</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">External and implanted pumps for apomorphine infusion in parkinsonism.</title>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical and Biological Neurosciences, INSERM U-318, Joseph Fourier University of Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM U-318, Joseph Fourier University of Grenoble</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A L" last="Benabid">A L Benabid</name>
</author>
<author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P" last="Limousin">P. Limousin</name>
</author>
<author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C L" last="Gervason">C L Gervason</name>
</author>
<author><name sortKey="Jeanneau Nicolle, E" sort="Jeanneau Nicolle, E" uniqKey="Jeanneau Nicolle E" first="E" last="Jeanneau-Nicolle">E. Jeanneau-Nicolle</name>
</author>
</analytic>
<series><title level="j">Acta neurochirurgica. Supplementum</title>
<imprint><date when="1993" type="published">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (therapeutic use)</term>
<term>Adult</term>
<term>Aged</term>
<term>Animals</term>
<term>Apomorphine (administration & dosage)</term>
<term>Apomorphine (pharmacology)</term>
<term>Apomorphine (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Infusion Pumps, Implantable</term>
<term>Macaca fascicularis</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Receptors, Dopamine (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Infusion Pumps, Implantable</term>
<term>Macaca fascicularis</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Continuous delivery of dopaminergic agents to the striatum is a major challenge to improve the treatment of Parkinson's disease. Apomorphine is one of the best candidates because of its solubility and its D1 and D2 receptor agonist properties. Seventeen Parkinsonian patients suffering from severe L-dopa-induced on-off effects were treated by continuous subcutaneous (SC) infusion with a portable minipump. Administration of intracerebroventricular (ICV) apomorphine was carried out in 7 macaca fascicularis monkeys using implanted programmable pumps. Four of the monkeys were made Parkinsonian by MPTP injections. In patients receiving apomorphine, the mean duration of daily off periods was reduced by 61%. Psychiatric side effects were rare but SC nodules occurred in all patients and the external infusion method was therefore difficult to implement. In monkeys, the implanted system was well tolerated. ICV apomorphine infusion led to CSF apomorphine concentrations higher than the same apomorphine dose infused i.m. Motor function was considerably improved in two MPTP monkeys during the time of ICV infusion and 30 min after its arrest. Long-term ICV administration could not be carried out because of catheter blockage and/or apomorphine toxicity. SC and ICV apomorphine infusions are efficient for controlling motor activity in Parkinsonism but long-term toxicity remains to be studied further.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8109301</PMID>
<DateCreated><Year>1994</Year>
<Month>03</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>1994</Year>
<Month>03</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>07</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>58</Volume>
<PubDate><Year>1993</Year>
</PubDate>
</JournalIssue>
<Title>Acta neurochirurgica. Supplementum</Title>
<ISOAbbreviation>Acta Neurochir Suppl (Wien)</ISOAbbreviation>
</Journal>
<ArticleTitle>External and implanted pumps for apomorphine infusion in parkinsonism.</ArticleTitle>
<Pagination><MedlinePgn>48-52</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Continuous delivery of dopaminergic agents to the striatum is a major challenge to improve the treatment of Parkinson's disease. Apomorphine is one of the best candidates because of its solubility and its D1 and D2 receptor agonist properties. Seventeen Parkinsonian patients suffering from severe L-dopa-induced on-off effects were treated by continuous subcutaneous (SC) infusion with a portable minipump. Administration of intracerebroventricular (ICV) apomorphine was carried out in 7 macaca fascicularis monkeys using implanted programmable pumps. Four of the monkeys were made Parkinsonian by MPTP injections. In patients receiving apomorphine, the mean duration of daily off periods was reduced by 61%. Psychiatric side effects were rare but SC nodules occurred in all patients and the external infusion method was therefore difficult to implement. In monkeys, the implanted system was well tolerated. ICV apomorphine infusion led to CSF apomorphine concentrations higher than the same apomorphine dose infused i.m. Motor function was considerably improved in two MPTP monkeys during the time of ICV infusion and 30 min after its arrest. Long-term ICV administration could not be carried out because of catheter blockage and/or apomorphine toxicity. SC and ICV apomorphine infusions are efficient for controlling motor activity in Parkinsonism but long-term toxicity remains to be studied further.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pollak</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Clinical and Biological Neurosciences, INSERM U-318, Joseph Fourier University of Grenoble, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Benabid</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Limousin</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gervason</LastName>
<ForeName>C L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jeanneau-Nicolle</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Austria</Country>
<MedlineTA>Acta Neurochir Suppl (Wien)</MedlineTA>
<NlmUniqueID>0140560</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9P21XSP91P</RegistryNumber>
<NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber>
<NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015918" MajorTopicYN="Y">Infusion Pumps, Implantable</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1993</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1993</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">8109301</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001687 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001687 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:8109301 |texte= External and implanted pumps for apomorphine infusion in parkinsonism. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8109301" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |